Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Complete title: ANBL1232, Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma. A Groupwide Historically Controlled Phase III Study

Research Study Number ANBL1232
Principal Investigator Julie Park, MD
Phase III

Research Study Description

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. Response and biology-based risk factor-guided therapy may be effective in treating patients with non-high risk neuroblastoma and may help to avoid some of the risks and side effects related to standard treatment.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number ANBL1232
Contact Laura Hill
Telephone 206/884-3002

Keywords: Pediatric Cancers, Miscellaneous; Neuroblastoma; Solid Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms; Neuroectodermal Tumors; Neoplasms, Glandular and Epithelial; Ganglioneuroblastoma; Neoplasms, Neuroepithelial

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials